GnRH‐a + raloxifene vs GnRH‐a ± placeboSeverity of vasomotor symptoms · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
GnRH‐a + raloxifene vs GnRH‐a ± placeboRate of vasomotor symptoms ‐ · patients with uterine fibroidsThe review found no eligible studies for this question.1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
SERMS (raloxifene 60mg) vs placeboSize (cm3) of leiomyoma · patients with uterine leiomyomas2 findings from 1 reviewSelective estrogen receptor modulators (SERMs) for uterine leiomyomas 2012 · Cochrane Headline outcomes onlyno estimate extracted1 study · 58 participantsLowSelective estrogen receptor modulators (SERMs) for uterine leiomyomas 2012 · Cochrane Headline outcomes onlyno estimate extracted1 study · 58 participantsLow
SERMS (raloxifene 60mg) vs placeboPercent change from baseline in leiomyoma size in GHRH‐analogue treated women · patients with uterine leiomyomas1 finding from 1 reviewSelective estrogen receptor modulators (SERMs) for uterine leiomyomas 2012 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
SERMS (raloxifene 180 mg) vs placeboSize (cm3) of leiomyoma · patients with uterine leiomyomas2 findings from 1 reviewSelective estrogen receptor modulators (SERMs) for uterine leiomyomas 2012 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsLowSelective estrogen receptor modulators (SERMs) for uterine leiomyomas 2012 · Cochrane Headline outcomes onlyno estimate extracted1 study · 59 participantsLow